Clinical trials
Aortic Valve Stenosis trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 3 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medtronic Cardiac Rhythm and Heart Failure | 3 |
| Charles University, Czech Republic | 2 |
| Institut für Pharmakologie und Präventive Medizin | 2 |
| Novartis Pharmaceuticals | 2 |
| Abbott Medical Devices | 1 |
| Clinical Centre of Serbia | 1 |
| Corcym S.r.l | 1 |
| Edwards Lifesciences | 1 |
| Medtronic Cardiovascular | 1 |
| Nemocnice AGEL Trinec-Podlesi a.s. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aortic Valve Stenosis | 19 |
| Cardiovascular Diseases | 4 |
| Heart Valve Diseases | 3 |
| Aortic Valve Disease | 2 |
| Heart Diseases | 2 |
| Calcinosis | 1 |
| Coronary Artery Disease | 1 |
| Dyslipidemias | 1 |
| Embolism and Thrombosis | 1 |
| Heart Failure | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.